Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide ...

On the plus side, the time that tirzepatide will stay under review at the FDA has just gotten shorter, as the FDA has granted the drug fast-track review that means it should make a decision within ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Tirzepatide was previously shown to provide sustained weight reductions in adults with obesity. New longer-term findings in adults with both obesity and prediabetes are summarized in a short video.

Obesity is a common health problem affecting a considerable (and growing) proportion of adult populations worldwide.1 Although overweight and obesity are usually diagnosed by anthropometry, such as ...

BOSTON, MA—Tirzepatide improves outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, no matter how much excess body weight they have, according to an analysis ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...

Two recent tools in the battle for weight loss have been showing incredible results: Semaglutide and Tirzepatide. Stephanie Davison from Skin Envy Non-Surgical Weight Loss Center, and Registered ...

The primary endpoint of the Phase 2 BMT-801 clinical trial is to demonstrate the safety and efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight. Patients were ...